89 results about "Biological therapies" patented technology

A system delivers cardiac pacing therapy and chemical and/or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that region, and a cardiac rhythm management (CRM) device to deliver pacing pulses to enhance the effects of the one or more agents by altering myocardial wall stress and cardiac workload. In one embodiment, the system is an implantable system including an implantable agent delivery device and an implantable CRM device.

Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.

The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies.

A system delivers combined ventricular assist device (VAD) therapy and chemical and/or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that region, and a VAD to enhance the effects of the one or more agents by reducing myocardial wall stress and the overall cardiac workload. In one embodiment, the system is an implantable system including an implantable agent delivery device and an implantable VAD for long-term use in a patient.

Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

The invention relates to an application of lactobacillus plantarum in preparation of food, health food, a health product or a medicine with a function of reducing blood fat or assisting fat-reducing. The collection number of the lactobacillus plantarum is CGMCC No.8198. the lactobacillus plantarum was collected in China General Microbiological Culture Collection Center (CGMCC) on Sep. 17, 2013. The address is 1 Beichen West Road, Chaoyang District, Beijing. The strain achieves the effect of reducing blood fat by reducing the level of serum cholesterol, triglyceride and low-density lipoprotein cholesterin. L.plantarum CGMCC No.8198 and its fermented products also play a role in controlling and reducing weight, and have an effect of assisting fat-reducing. The invention provides a biological therapy for effectively reducing serum cholesterol and assisting fat-reducing. The biological therapy has long-term eating safety and has a considerable application prospect.

The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and/or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and/or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of thalidomide alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of thalidomide. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

The present disclosure describes systems and methods for mimicking body tissue and the function thereof. The mimicked body tissue can include kidney tissue, the blood brain barrier, and other tissues. In some implementations, the systems described herein are used to test the impact of controlled factors on the tissue. The controlled factors can include flow rates, shear rates, and test chemicals (e.g., therapeutics and toxins). In some implementations, the system and methods are used to test pharmaceutical and biological therapies, characterize healthy or diseased tissue, and observe phenomena of the tissue in vitro.

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

The invention relates to a composite of SiO2Au nuclear shell structure nano material and biological protein medicament. The composite is prepared through grafting the SiO2Au nuclear shell structure nano material with the biological protein medicament by Au-S bond, and closing rest non-active sites of the SiO2Au nuclear shell structure nano material by sulphane polyethylene glycol. A preparation method comprises the following steps: (1) making amino polyethylene glycol and 2-imino sulphane according to a molar ratio of 1 to 1 reacted in potassium carbonate solution for 1 hour, dialyzing and purifying the reagents by secondary distilled water, and obtaining the sulphane polyethylene glycol; and (2) mixing the SiO2Au nuclear shell structure nano material, the biological protein medicament and the 2-imino sulphane in the potassium carbonate solution, standing over night, adding the mixture into the sulphane polyethylene glycol obtained in step (1) for reaction under the condition of weak alkali buffer solution, so as to obtain the composite. The composite compounds physical therapy of inorganic nano particles and biological therapy function of protein medicament, remarkably improves treatment effect for tumor, and can be used a new anticancer medicament.

The present invention relates to benzo-isoselenazole derivative and its pharmaceutically acceptable salt. The derivative may be used in immunological regulation and biological therapy and as health composition with immunological regulation function.

The present invention relates to one kind of specific heat shock protein extracting kit, and the extracting kit consists of heat shock protein affinity resin or heat shock protein affinity chromatographic column and may have matched mother liquid for affinity chromatography. The present invention aims at extracting heat shock protein or heat shock protein-polypeptide complex conveniently, fast, effectively and specifically from tissue or cell. The heat shock protein-polypeptide complex antigen extracted with the heat shock protein extracting kit is used in preventing and treating diseases caused by self cell mutation, foreign pathogen infection, autoimmune deficiency, etc.

The invention discloses application of ferroferric oxide as a photo-thermal sensitive material. According to the application, ferroferric oxide is radiated by near-infrared light to generate heat and is irradiated by laser with the wavelength of 700-2000nm; Fe3O4 is found to have a favorable photo-thermal effect for the first time and is a potential photo-thermal sensitive agent; the Fe3O4 has a certain application prospect in the aspect of photo-thermal conversion, in particular to the aspect of biological therapy; in addition, the Fe3O4 has remarkable photo-thermal effect and biological therapy effect; specific cytotoxicity of tumor can be realized by irradiating the Fe3O4 for five minutes; after treatment, the tumor is completely removed; the Fe3O4 has no remarkable influence on normal tissues; relative to treatment methods such as operation and chemotherapy, the Fe3O4 is remarkable in curative effect and small in toxic or side effect; and meanwhile, the Fe3O4 integrates various special functions such as magnetic targeting and magnetic resonance imaging, so that the Fe3O4 has broad application prospect in aspects of clinical diagnosis and treatment.

The invention belongs to the technical field of biomedicines and in particular relates to a construction method and application of a double-target-spot DNA (Deoxyribonucleic Acid) nano therapy system.The construction method comprises the following steps: dissolving six single-stranded linear-chain DNA into an in-vitro buffer salt solution; carrying out annealing and self-assembling to form a DNAtetrahedron solution; adding crosslinking agent Sulfo-SMCC powder into a 5'-end C6 amino modified ssDNA solution; reacting at room temperature for 2h; removing an unreacted crosslinking agent and thenadding polypeptide powder; reacting at the room temperature for 12h and removing excessive polypeptide to obtain ssDNA-peptide; adding the ssDNA-peptide into the DNA tetrahedron solution, so as to finish construction of the double-target-spot DNA nano therapy system. According to the construction method provided by the invention, a constructed DNA tetrahedron carrier has a stable structure; aftera medicine is loaded on the carrier, the stability of a polypeptide medicine can be improved; the double-target-spot DNA nano therapy system has relatively strong targeting performance and mainly express a biological therapy effect through regulating and controlling a cell signal path.

The invention relates to a macrophage tumor targeting therapy system combining a photothermal therapy effect and photo-thermally responsive biotherapeutic factor release and preparation and application thereof. The unique spatial and temporal selectivity of the macrophage tumor targeting therapy system can direct at a variety of solid malignant tumors, combines tumor photo-thermal therapy with biological therapy to achieve the local targeted comprehensive treatment of the tumors and reduce the toxic and side effects of traditional treatment caused by an off-target effect. The macrophage targeting tumor system can effectively inhibit the tumor growth of mice and prolong the survival time of the tumor-bearing mice, is an excellent tumor-targeting biological preparation and has great clinicalconversion application prospects.

The invention discloses a metal organic framework composite nanomaterial with targeting property and pH responsiveness as well as a preparation method and application of the metal organic framework composite nanomaterial. The metal organic framework composite nanomaterial is prepared from protein-loaded ZIF-8 metal organic framework nano-particles, calcium carbonate structures wrapping the ZIF-8 nano-particles and aptamers fixed to calcium carbonate structures. The preparation method is simple and convenient to operate, and damage to protein activity is avoided. The composite nano material provided by the invention has good protein loading capacity and targeting performance, and can gradually release contents in a low pH environment. The metal organic framework composite nanomaterial disclosed by the invention can also target T cells to increase the number of intracellular anti-tumor active substances, and can be developed into a novel anti-tumor biological therapy.